Search
LP-2307
go.drugbank.com/drugs/DB17470ExperimentalLP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
ALLO-605
go.drugbank.com/drugs/DB18641InvestigationalALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).
RC88
go.drugbank.com/drugs/DB18697ExperimentalRC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
TBI-223
go.drugbank.com/drugs/DB18911InvestigationalTBI-223 is under investigation in clinical trial NCT06192160 (Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis).
Synonyms: CARBAMIC ACID, N-(((5S)-3-(3-FLUORO-4-(2-OXA-6-AZASPIRO(3.3)HEPT-6-YL)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-, METHYL ESTERRovadicitinib
go.drugbank.com/drugs/DB21747InvestigationalRovadicitinib is under investigation in clinical trials NCT06682169 and NCT06300320 for the treatment of Chronic Graft-versus-host Disease.
Coagulation factor XIa
go.drugbank.com/drugs/DB15420InvestigationalCoagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).
ATX-F8-117
go.drugbank.com/drugs/DB17712ExperimentalATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]
BHV-5000
go.drugbank.com/drugs/DB17817ExperimentalBHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]
inBreath airway transplant system
go.drugbank.com/drugs/DB18692ExperimentalinBreath airway transplant system composes of a scaffold seeded with autologous bone marrow cells and incubated in the bioreactor for two days prior to implant.
Psilocybin
go.drugbank.com/drugs/DB11664InvestigationalIn November, 2019, it was granted Breakthrough Therapy status by the FDA.